Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy

International Journal of Oncology

Volumn 29, Issue 4, 2006, Pages 919-933

  Bachvarov, Dimcho ^a,b   L'Esperance, Sylvain ^a,b   Popa, Ion ^a,b   Bachvarova, Magdalena ^b   Plante, Marie ^a,b   Têtu, Bernard ^a,b  

^a UNIVERSITÉ LAVAL   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

DNA microarray; Gene expression; Gene predictor set; Response to chemotherapy; Serous epithelial ovarian cancer

Indexed keywords

AGED; ARTICLE; CARCINOMA; CLASSIFICATION; COMPARATIVE STUDY; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; MIDDLE AGED; OVARY TUMOR; TUMOR GENE;

AGED; AGED, 80 AND OVER; CARCINOMA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENES, NEOPLASM; HUMANS; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS;

EID: 34547746921     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.4.919     Document Type: Article

References (81)

1. Wingo PA, Tong T and Bolden S: Cancer statistics. CA Cancer J Clin 45: 8-30, 1995.
2. Ozols RF: Current status of CT for ovarian cancer. Semin Oncol 22: 61-66, 1995.
3. Dunton CJ: New options for the treatment of advanced ovarian cancer. Semin Oncol 24: S5-2-S5-11, 1997.
4. Markman M: Current status and future directions of platinum/paclitaxel- based CT of ovarian cancer. Semin Oncol 24: S11-24-S11-27, 1997.
5. Bookman MA, McGuire WP III, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH and Ozols RF: Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14: 1895-1902, 1996.
6. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6, 1996.
7. Ozols RF: Optimum CT for ovarian cancer. Int J Gynecol Cancer 10: 33-37, 2000.
8. Du Bois A, Luck HJ, Pfisterer J, Schroeder W, Blohmer JU, Kimmig R, Moebus V and Quaas J: Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer - a dose-finding study by the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 12: 1115-1120, 2001.
9. Kita T, Kikuchi Y, Hirata J and Nagata I: Prognosis of ovarian cancer today. Cancer J 11: 201-207, 1998.
10. Pegg AE and Byers TL: Repair of DNA containing O6-alkylguanine. FASEB J 6: 2302-2310, 1992.
11. Eastman A and Schulte N: Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). Biochemistry 27: 4730-4734, 1998.
12. Yao KS, Godwin AK, Johnson SW, Ozols RF, O'Dwyer PJ and Hamilton TC: Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55: 4367-4374, 1995.
13. Vanderzee AGJ, Vanommen B, Meijer C, Hollema H, Vanbladeren PJ and Devries EGE: Glutathione-S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours and malignant ovarian tumours after platinum/cyclophosphamide CT. Br J Cancer 66: 930-936, 1992.
14. Shridhar V, Bible KC, Staub J, Avula R, Lee YK, Kalli K, Huang H, Hartmann LC, Kaufmann SH and Smith DI: Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res 61: 4258-4265, 2001.
15. Hengstler JG, Lange J, Kett A, Dornhofer N, Meinert R, Arand M, Knapstein PG, Becker R, Oesch F and Tanner B: Contribution of c-erbB-2 and topoisomerase IIα to chemoresistance in ovarian cancer. Cancer Res 59: 3206-3214, 1999. (Pubitemid 29316024)
16. Liu JR, Fletcher B, Page C, Hu C, Nunez G and Baker V: Bcl-xL is expressed in ovarian carcinoma and modulates CT-induced apoptosis. Gynecol Oncol 70: 398-403, 1998. (Pubitemid 28473641)
17. Sasaki H, Sheng Y, Kotsuji F and Tsang BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 60: 5659-5666, 2000.
18. Li J, Feng Q, Kim JM, Schneiderman D, Liston P, Li M, Vanderhyden B, Faught W, Fung MF, Senterman M, Korneluk RG and Tsang BK: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142: 370-380, 2001.
19. Germain I, Têtu B, Brisson J, Mondor M and Cherian G: Markers of chemoresistance in ovarian carcinomas; an immunohistochemical study of 86 cases. Int J Gynecol Pathol 15: 54-62, 1996. (Pubitemid 26009671)
20. Eltabbakh GH and Awtrey CS: Current treatment for ovarian cancer. Expert Opin Pharmacother 2: 109-124, 2001.
21. Goff BA, Paley PJ, Greer BE and Gown AM: Evaluation of chemoresistance markers in women with epithelial ovarian carcinoma. Gynecol Oncol 81: 18-24, 2001.
22. Schmidt U and Begley CG: Cancer diagnosis and microarrays. Int J Biochem Cell Biol 35: 119-124, 2003.
23. Liu ET: Classification of cancers by expression profiling. Curr Opin Genet Dev 13: 97-103, 2003.
24. Raetz EA and Moos PJ: Impact of microarray technology in clinical oncology. Cancer Invest 22: 312-320, 2004.
25. Cuperlovic-Culf M, Belacel N and Ouellette RJ: Determination of tumour marker genes from gene expression data. Drug Discov Today 10: 429-437, 2005. (Pubitemid 40450273)
26. Mariadason JM, Augenlicht LH and Arango D: Microarray analysis in the clinical management of cancer. Hematol Oncol Clin North Am 17: 377-387, 2003. (Pubitemid 36514558)
27. Wulfkuhle J, Espina V, Liotta L and Petricoin E: Genomic and proteomic technologies for individualisation and improvement of cancer treatment. Eur J Cancer 40: 2623-2632, 2004.
28. Alaoui-Jamali MA, Dupre I and Qiang H: Prediction of drug sensitivity and drug resistance in cancer by transcriptional and proteomic profiling. Drug Resist Update 7: 245-255, 2004. (Pubitemid 39469097)
29. Wang Y: Gene expression-driven diagnostics and pharmacogenomics in cancer. Curr Opin Mol Ther 7: 246-250, 2005. (Pubitemid 40790548)
30. Auersperg N, Wong AS, Choi KC, Kang SK and Leung PC: Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255-288, 2001.
31. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
32. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr and Lu KH: Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11: 6116-6126, 2005.
33. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
34. L'Esperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L, Têtu B and Bachvarov D: Gene expression profiling of paired tumor samples obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol 29: 5-24, 2006.
35. Ambroise C and McLachlan GJ: Selection bias in gene extraction on the basis of microarray gene-expression data. Proc Natl Acad Sci USA 99: 6562-6566, 2002.
36. Simon R, Radmacher MD, Dobbin K and McShane LM: Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 95: 14-18, 2003. (Pubitemid 36124291)
37. Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D and Rapoport AP: PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis 27: 825-829, 2001.
38. Su B, Guan M, Zhao R and Lu Y: Expression of prostaglandin D synthase in ovarian cancer. Clin Chem Lab Med 39: 1198-1203, 2001.
39. Spataro V, Toda T, Craig R, Seeger M, Dubiel W, Harris AL and Norbury C: Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit. J Biol Chem 272: 30470-30475, 1997.
40. Yuce K, Baykal C, Genc C, Al A and Ayhan A: Diagnostic and prognostic value of serum and peritoneal fluid lactate dehydrogenase in epithelial ovarian cancer. Eur J Gynaecol Oncol 22: 228-232, 2001.
41. Wang H, Liu S, Lu X, Zhao X, Chen S and Li X: Gene expression profile changes in NB4 cells induced by realgar. Chin Med J 116: 1074-1077, 2003.
42. Burns KH, Owens GE, Ogbonna SC, Nilson JH and Matzuk MM: Expression profiling analyses of gonadotropin responses and tumor development in the absence of inhibins. Endocrinology 144: 4492-4507, 2003.
43. Cheng Q, Lau WM, Tay SK, Chew SH, Ho TH and Hui KM: Identification and characterization of genes involved in the carcinogenesis of human squamous cell cervical carcinoma. Int J Cancer 98: 419-426, 2002.
44. Tarantul VZ and Hunsmann G: Mitochondrial polypeptides of the oxidative phosphorylation pathway as potential new targets for anti-cancer therapy. Med Hypotheses 56: 386-387, 2001.
45. Perumal SS, Shanthi P and Sachdanandam P: Therapeutic effect of tamoxifen and energy-modulating vitamins on carbohydrate-metabolizing enzymes in breast cancer. Cancer Chemother Pharmacol 56: 105-114, 2005.
46. Zhu NX, Zheng S, Xu RZ, Gao RL, Shen JP and Yu RX: Identification of multidrug resistance related genes in leukemia by suppression subtractive hybridization. Zhonghua Xue Ye Xue Za Zhi 24: 14-17, 2003.
47. Shen XY, Zacal N, Singh G and Rainbow AJ: Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells. Photochem Photobiol 81: 306-313, 2005. (Pubitemid 40551506)
48. Chu F, Barkinge J, Hawkins S, Gudi R, Salgia R and Kanteti PV: Expression of Siva-1 protein or its putative amphipathic helical region enhances cisplatin-induced apoptosis in breast cancer cells: effect of elevated levels of BCL-2. Cancer Res 65: 5301-5309, 2005. (Pubitemid 40827342)
49. Yeh CS, Wang JY, Cheng TL, Juan CH, Wu CH and Lin SR: Fatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by Microarray-Bioinformatics analysis. Cancer Lett 233: 297-308, 2006.
50. Higo M, Uzawa K, Kouzu Y, Bukawa H, Nimura Y, Seki N and Tanzawa H: Identification of candidate radioresistant genes in human squamous cell carcinoma cells through gene expression analysis using DNA microarrays. Oncol Rep 14: 1293-1298, 2005.
51. Tanner B, Hengstler JG, Dietrich B, Henrich M, Steinberg P, Weikel W, Meinert R, Kaina B, Oesch F and Knapstein PG: Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. Gynecol Oncol 65: 54-62, 1997.
52. Bouras T, Southey MC, Chang AC, Reddel RR, Willhite D, Glynne R, Henderson MA, Armes JE and Venter DJ: Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer. Cancer Res 62: 1289-1295, 2002. (Pubitemid 34407780)
53. Song BL, Wang CH, Yao XM, Yang L, Zhang WJ, Wang ZZ, Yang JB, Qi W, Yang XY, Inoue K, Lin ZX, Zhang HZ, Kodama T, Chang CC, Liu YK, Chang TY and Li BL: Human acyl-CoA: cholesterol acyltransferase 2 gene expression in intestinal Caco-2 cells and in hepatocellular carcinoma. Biochem J 394: 617-626, 2006.
54. Yamamoto Y, Sakamoto M, Fujii G, Tsuiji H, Kenetaka K, Asaka M and Hirohashi S: Overexpression of orphan G-protein-coupled receptor, Gpr49, in human hepatocellular carcinomas with beta-catenin mutations. Hepatology 37: 528-533, 2003. (Pubitemid 36258773)
55. Hu W, Wu W, Verschraegen CF, Chen L, Mao L, Yeung SC, Kudelka AP, Freedman RS and Kavanagh JJ: Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor. Proteomics 10: 1904-1911, 2003.
56. Cao QJ, Belbin T, Socci N, Balan R, Prystowsky MB, Childs G and Jones JG: Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 23: 321-329, 2004. (Pubitemid 39299020)
57. Dobbin K and Simon R: Comparison of microarray designs for class comparison and class discovery. Bioinformatics 18: 1438-1445, 2002. (Pubitemid 35414534)
58. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M and Terakawa N: Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100: 281-287, 2002. (Pubitemid 34874791)
59. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F and Pantel K: Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Cancer Res 11: 3678-3685, 2005.
60. Linn SC, Pinedo HM, van Ark-Otte J, van der Valk P, Hoekman K, Honkoop AH, Vermorken JB and Giaccone G: Expression of drug resistance proteins in breast cancer, in relation to CT. Int J Cancer 71: 787-795, 1997.
61. Yang KP, Liang YF and Samaan NA: Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with overexpression of mdrl gene and low proliferation fraction. Anticancer Res 11: 1065-1068, 1991.
62. Jazaeri AA, Awtrey CS, Chandramouli GV, Chuang YE, Khan J, Sotiriou C, Aprelikova O, Yee CJ, Zorn KK, Birrer MJ, Barrett JC and Boyd J: Gene expression profiles associated with response to CT in epithelial ovarian cancers clinical cancer. Clin Cancer Res 11: 6300-6310, 2005.
63. Huang Y, Anderle P, Bussey KJ, Barbacioru C, Shankavaram U, Dai Z, Reinhold WC, Papp A, Weinstein JN and Sadee W: Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64: 4294-4301, 2004.
64. Schmidt WM, Kalipciyan M, Dornstauder E, Rizovski B, Steger GG, Sedivy R, Mueller MW and Mader RM: Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer 112: 200-212, 2004.
65. Huang Y and Sadee W: Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett 239: 336-349, 2006 (Epub 2005 Oct 5).
66. Chin K-V, Ueda K, Pastan I and Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-562, 1992.
67. Volm M, Kastel M, Mattern J and Efferth T: Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer 71: 3981-3987, 1993.
68. Sabbatini ARM, Basolo F, Valentini P, Mattii L, Calvo S, Fiore L, Ciardiello F and Petrini M: Induction of multidrug resistance (MDR) by transfection of MCF-10A cell line with c-Ha-ras and c-erbB-2 oncogenes. Int J Cancer 59: 208-211, 1994.
69. Beck SA, Groundwater P, Barton C and Tisdale MJ: Alterations in serum lipolytic activity of cancer patients with response to therapy. Br J Cancer 62: 822-825, 1990. (Pubitemid 20362154)
70. Gercel-Taylor C, Doering DL, Kraemer FB and Taylor DD: Aberrations in normal systemic lipid metabolism in ovarian cancer patients. Gynecol Oncol 60: 35-41, 1996.
71. Altinoz MA and Korkmaz R: NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 51: 239-247, 2004.
72. Hennigan RF, Hawker KL and Ozanne BW: Fos-transformation activates genes associated with invasion. Oncogene 9: 3591-3600, 1994.
73. Wansa KD and Muscat GE: TRAP220 is modulated by the antineoplastic agent 6-Mercaptopurine, and mediates the activation of the NR4A subgroup of nuclear receptors. J Mol Endocrinol 34: 835-848, 2005.
74. Woong-Shick A, Sung-Pil P, Su-Mi B, Joon-Mo L, Sung-Eun N, Gye-Hyun N, Young-Lae C, Ho-Sun C, Heung-Jae J, Chong-Kook K, Young-Wan K, Byoung-Don H and Hyun-Sun J: Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci 96: 197-201, 2005.
75. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, De Geest K, Hartenbach EM and Baergen R: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21: 3194-3200, 2003.
76. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S and Sickel J: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001-1007, 2001.
77. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA and Damokosh AI: Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel CT. Clin Cancer Res 11: 2149-2155, 2005.
78. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR and Marks JR: Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3896, 2005.
79. Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA and Cannistra SA: Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 23: 7911-7918, 2005. (Pubitemid 46657390)
80. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA and Cannistra SA: Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700-4710, 2004.
81. Helleman J, Jansen MP, Span PN, van Staveren IL, Massuger LF, Meijer-van Gelder ME, Sweep FC, Ewing PC, van der Burg ME, Stoter G, Nooter K and Berns EM: Molecular profiling of platinum resistant ovarian cancer. Int J Cancer 118: 1963-1971, 2006.